Acute portal vein thrombosis in noncirrhotic patients–different prognoses based on presence of inflammatory markers: a long-term multicenter retrospective analysis

KEIL, Radan, J KOŽELUHOVÁ, Jiří DOLINA, Aleš HEP, Radek KROUPA, Vladimír KOJECKÝ, T KREJČÍ, J HAVLÍN, I HADAČOVÁ, J SEGETHOVÁ, P KOPTOVÁ, Z ZÁDOROVÁ, J MATOUŠ, B FRÝBOVÁ, P CHMÁTAL, M WASSERBAUER, J ŠŤOVÍČEK, M BAE, T GUVEN, M ZAEEM a Š HLAVA. Acute portal vein thrombosis in noncirrhotic patients–different prognoses based on presence of inflammatory markers: a long-term multicenter retrospective analysis. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. Informa Healthcare, 2019, roč. 54, č. 11, s. 1379-1384. ISSN 0425-4929. Dostupné z: https://dx.doi.org/10.1080/00365521.2019.1677768.

Základní údaje

• Originální název: Acute portal vein thrombosis in noncirrhotic patients–different prognoses based on presence of inflammatory markers: a long-term multicenter retrospective analysis
• Autoři: KEIL, Radan, J KOŽELUHOVÁ, Jiří DOLINA, Aleš HEP, Radek KROUPA, Vladimír KOJECKÝ, T KREJČÍ, J HAVLÍN, I HADAČOVÁ, J SEGETHOVÁ, P KOPTOVÁ, Z ZÁDOROVÁ, J MATOUŠ, B FRÝBOVÁ, P CHMÁTAL, M WASSERBAUER, J ŠŤOVÍČEK, M BAE, T GUVEN, M ZAEEM a Š HLAVA.
• Vydání: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, Informa Healthcare, 2019, 0425-4929.

Další údaje

• Originální jazyk: angličtina
• Typ výsledku: Článek v odborném periodiku
• Obor: 30219 Gastroenterology and hepatology
• Utajení: není předmětem státního či obchodního tajemství
• WWW: URL
• Doi: http://dx.doi.org/10.1080/00365521.2019.1677768
• UT WoS: 000491464500001
• Klíčová slova anglicky: Acute portal vein thrombosis; hemato-oncologic disease; prothrombotic factors

Anotace

Background: Portal vein thrombosis (PVT) is a partial or complete thrombotic occlusion of the portal vein and is rare in noncirrhotic patients. Patients and methods: 78 adult patients with noncirrhotic acute PVT without known malignity were evaluated. Patients with initial CRP level 61–149 mg/l were excluded. Results: Patients were divided into two groups–the first one (33 patients) was characterized with signs of inflammation and CRP over 149 mg/l. The second group (45 patients) was without signs of inflammation and CRP level less than 61 mg/l. The frequency of prothrombotic hematologic factors was statistically significantly different in levels of factor VIII and MTHFR 677 C mutation. All patients from both groups underwent the same oncologic and hemato-oncologic screening which was positive in 23 patients (51.1%) in the group without signs of inflammation. In the group of patients with clinical and laboratory signs of inflammation oncologic and hemato-oncologic screening was positive only in 1 patient (3.0%). Complete portal vein recanalization was achieved in 19.2%, partial recanalization in 26.9%. Conclusions: Patients with clinical signs of inflammation and acute PVT have a low risk of malignancy in contrast to patients without signs of inflammation and acute PVT, which have a high risk of oncologic or hemato-oncologic disease. Patients with negative hemato-oncologic screening should be carefully observed over time because we expect they are at higher risk for the development of hemato-oncologic disease, independent from the presence and number of procoagulation risk factors.